Category: General - Part 6

Phase 2 Data With RHB-104 In Multiple Sclerosis Expected Soon

Several months ago I wrote an article highlighting RedHill Biopharma’s (NASDAQ: RDHL) RHB-104, a patent-protected combination of clarithromycin, clofazimine, and rifabutin in a single oral pill, currently in Phase 3 trials for the treatment of Crohn’s disease (CD). I encourage investors to view that article >> HERE << because it provides a very good background on RHB-104…

Actinium’s Place Among The CAR-T Hype and Radiopharma Busts

Shares of Actinium Pharmaceuticals (ATNM) have moved significantly higher over the past month as investors are starting to come to grips with the potential for the company’s two pipeline products, Iomab-B and Actimab-A, both under investigation for the treatment of acute myeloid leukemia (AML). Iomab-B and Actimab-A are specific anti-cancer monoclonal antibodies (mAb) conjugated to alpha…

22nd Century Group Files For Modified Risk Cigarette With FDA

Last month I wrote a detailed article introducing investors to 22nd Century Group, Inc. (NYSEMKT:XXII), a Clarence, NY-based biopharmaceutical company founded in 1998 with proprietary technology in nicotine biosynthesis and tobacco plant-biotechnology. The company is engaged in the development and commercialization of tobacco harm reduction cigarettes and smoking cessation products, as well as the contract…

Why You Should Get To Know 22nd Century Group

Yes, investors, there are still millions of people who smoke cigarettes! Bafflingly, despite all the science and meta-analyses, U.S. Surgeon General warnings and CDC case studies, the World Health Organization (WHO) estimates 5.6 trillion cigarettes were sold globally in 2014. Forty percent of these sales took place in Asia, where roughly two-thirds of the population…

Actinium Presents Strong Data on Actimab-A at Annual ASH Meeting

Actinium Pharmaceuticals (NYSEMKT: ATNM) had a very successful showing at the American Society of Hematology (ASH) annual meeting held over the past few days in Orlando, FL. The highlight of the event for the company was a poster presentation of Phase 1 clinical data with Actimab-A, the company’s CD33 targeting alpha particle immunotherapy for the…

Actinium Pharmaceuticals: An Impressive Platform Targeting Leukemia

Acute Leukemia – A Quick Overview Leukemias are cancers of the blood and involve bone marrow, circulating white blood cells, and organs such as the spleen and lymph nodes. The cancer usually manifests in the bone marrow and results in a high number of abnormal white blood cells called blasts (also called leukemia cells). The…

Depomed Is Cheap, By Almost Any Measure

I’m long Depomed (DEPO). Here is my model: Depomed has now raised guidance two quarters in a row (Q2, Q3). I think the current guidance is still conservative. Management is guiding to revenues between $336 million and $348 million for 2015. I model $344 million, with most of the growth coming from Nucynta / ER. Upside…

Can-Fite’s Preclinical ED Drug: Is There A Method To This Madness?

“Though this be madness, yet there is method in ’t” – Hamlet: Act II, Sc 2 If you watch a lot of television, especially things like the National Football League (NFL) or PGA Tour golf, or even CNBC, it is virtually impossible to go through a sitting without seeing a commercial for an erectile dysfunction…

RedHill Biopharma’s RHB-104: A Potential Game Changer for Crohn’s Disease?

Last week I wrote an article on Immune Pharmaceuticals (IMNP) and its first-in-class fully human IgG4 monoclonal antibody, bertilimumab, for the treatment of inflammatory bowel disease (IBD). Immune’s drug is currently in a Phase 2 trial targeting patients with moderate-to-severe ulcerative colitis (UC). Investors can view that article here >> LINK I spent a lot…